Supplementary Table 2. National estimates of unique patients receiving buprenorphine products for OUD, 2003-2021, from IQVIA Total Patient Tracker (TPT) ®

|  |  |  |
| --- | --- | --- |
| Year | Estimated Number of Patients from IQVIA | Retail Channel Coverage |
| 2003 | 19,026 |  |
| 2004 | 63,174 |  |
| 2005 | 108,325 |  |
| 2006 | 170,005 | 74% |
| 2007 | 288,677 | 74% |
| 2008 | 436,904 | 74% |
| 2009 | 517,292 | 74% |
| 2010 | 603,494 | 74% |
| 2011 | 710,244 | 74% |
| 2012 | 730,890 | 74% |
| 2013 | 774,276 | 78% |
| 2014 | 861,312 | 86% |
| 2015 | 914,792 | 86% |
| 2016 | 1,003,521 | 88% |
| 2017 | 1,113,512 | 90% |
| 2018 | 1,186,830 | 92% |
| 2019 | 1,295,524 | 92% |
| 2020 | 1,361,265 | 92% |
| 2021 | 1,440,878 | 93% |

The table includes buprenorphine products associated with USC 78340 (drug dependence). Therefore, we excluded buprenorphine products approved to treat pain (categorized as USC 022XX). Included products were Bunavail®, buprenorphine/naloxone, buprenorphine, Probuphine®, Sublocade®, Suboxone®, and Zubsolv®. For calendar year 2021, the coverage of retail pharmacy prescriptions is 80%-90% in Arkansas, Kansas, North Dakota, Nebraska, New York, Oklahoma, and South Dakota. The coverage is over 90% in the remaining states.